Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW to Boost Confirmation Process for Review Panel Members’ Claims on Money Received from Drug Makers
March 1, 2016
- MHLW Approves Add’l Indications for Halaven, Rituxan; Opdivo Now OK’ed for Previously Treated Patients
March 1, 2016
- MHLW Panel Backs Orphan Drug Designation for Opdivo for Hodgkin’s Lymphoma
February 29, 2016
- MHLW Advisory Panel Supports Novartis’s Ceritinib, AZ’s Osimertinib
February 29, 2016
- PMDA Reviewing Risks of Intestinal Obstruction for Loxoprofen
February 29, 2016
- Kaketsuken Allowed to Ship Japanese Encephalitis Vaccine
February 29, 2016
- Drug Makers, Distributors Rolling Up Their Sleeves for Mandatory Barcode Labeling
February 26, 2016
- MHLW Grants Orphan Designation to Takeda’s MM Drug Ixazomib
February 26, 2016
- MHLW Panel Backs Approval of Sanofi’s Antiepileptic Drug, OKs Cymbalta’s New Indication by Unanimous Vote
February 25, 2016
- Industry Must Find Logical Reasons to Dodge Re-Pricing amid Growing Pressure on Huge Sellers
February 24, 2016
- Possible Price Slash for Big-Sellers Looms as 2017 Tax Hike Nears; All Eyes on Opdivo
February 24, 2016
- MHLW Taskforce on Vaccines and Blood Products Holds 2nd Meeting
February 23, 2016
- Pricing Debate Spills Over into MHLW Safety Panel, Member Warns Opdivo Costs Could Jeopardize State Finances
February 22, 2016
- Next Invitation for Sakigake Pathway Might Not Happen Until FY2017, Designations Likely to Decrease: Official
February 18, 2016
- Terms of Emergency Deliveries Emerge as New Challenge amid Growing Generic Use
February 17, 2016
- Add Rhabdomyolysis to Nexium Label: MHLW
February 17, 2016
- LDP Lawmaker Questions “Huge Seller” Re-Pricing
February 17, 2016
- Cause of Post-HPV Vaccine Symptoms Can’t Be Immediately Elucidated: Govt
February 16, 2016
- 22 Firms Win Approvals for Zyprexa Generics for June Listing; Kipres AGs Also OK’ed
February 16, 2016
- MHLW to Hold Supplementary Review on Cymbalta’s New Pain Indication
February 16, 2016
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…